image
Healthcare - Medical - Devices - NASDAQ - US
$ 4.2
-0.943 %
$ 217 M
Market Cap
-4.29
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one SGHT stock under the worst case scenario is HIDDEN Compared to the current market price of 4.2 USD, Sight Sciences, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one SGHT stock under the base case scenario is HIDDEN Compared to the current market price of 4.2 USD, Sight Sciences, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one SGHT stock under the best case scenario is HIDDEN Compared to the current market price of 4.2 USD, Sight Sciences, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart SGHT

image
$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.015 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
79.9 M REVENUE
-1.47%
-50.5 M OPERATING INCOME
11.77%
-51.5 M NET INCOME
7.27%
-22.4 M OPERATING CASH FLOW
52.63%
-385 K INVESTING CASH FLOW
51.33%
4.96 M FINANCING CASH FLOW
349.64%
17.5 M REVENUE
-8.21%
-13.9 M OPERATING INCOME
-16.18%
-14.2 M NET INCOME
-19.48%
-11.6 M OPERATING CASH FLOW
-235.50%
0 INVESTING CASH FLOW
100.00%
16 K FINANCING CASH FLOW
-99.70%
Balance Sheet Sight Sciences, Inc.
image
Current Assets 140 M
Cash & Short-Term Investments 120 M
Receivables 10.8 M
Other Current Assets 8.63 M
Non-Current Assets 3.06 M
Long-Term Investments 0
PP&E 2.52 M
Other Non-Current Assets 550 K
84.26 %7.55 %6.04 %Total Assets$142.8m
Current Liabilities 15.5 M
Accounts Payable 1.69 M
Short-Term Debt 533 K
Other Current Liabilities 13.2 M
Non-Current Liabilities 39.8 M
Long-Term Debt 39.8 M
Other Non-Current Liabilities 19 K
3.06 %23.94 %72.00 %Total Liabilities$55.3m
EFFICIENCY
Earnings Waterfall Sight Sciences, Inc.
image
Revenue 79.9 M
Cost Of Revenue 11.6 M
Gross Profit 68.3 M
Operating Expenses 119 M
Operating Income -50.5 M
Other Expenses 975 K
Net Income -51.5 M
80m80m60m60m40m40m20m20m00(20m)(20m)(40m)(40m)(60m)(60m)80m(12m)68m(119m)(51m)(975k)(52m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
85.50% GROSS MARGIN
85.50%
-63.27% OPERATING MARGIN
-63.27%
-64.49% NET MARGIN
-64.49%
-58.85% ROE
-58.85%
-36.06% ROA
-36.06%
-39.69% ROIC
-39.69%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Sight Sciences, Inc.
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)(80m)(80m)20192019202020202021202120222022202320232024202420252025
Net Income -51.5 M
Depreciation & Amortization 712 K
Capital Expenditures -385 K
Stock-Based Compensation 17.1 M
Change in Working Capital 9 M
Others 5.86 M
Free Cash Flow -22.7 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Sight Sciences, Inc.
image
Wall Street analysts predict an average 1-year price target for SGHT of $7.25 , with forecasts ranging from a low of $4 to a high of $10 .
SGHT Lowest Price Target Wall Street Target
4 USD -4.76%
SGHT Average Price Target Wall Street Target
7.25 USD 72.62%
SGHT Highest Price Target Wall Street Target
10 USD 138.10%
Price
Max Price Target
Min Price Target
Average Price Target
10109988776655443322Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 13
6. Ownership
Insider Ownership Sight Sciences, Inc.
image
Sold
0-3 MONTHS
193 K USD 5
3-6 MONTHS
233 K USD 4
6-9 MONTHS
2.76 M USD 7
9-12 MONTHS
219 K USD 5
Bought
828 K USD 1
0-3 MONTHS
53.2 K USD 1
3-6 MONTHS
2.12 M USD 2
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Sight Sciences to Present at the Stifel 2025 Virtual Ophthalmology Forum on May 27th MENLO PARK, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced plans to present at the Stifel 2025 Virtual Ophthalmology Forum. globenewswire.com - 1 month ago
Sight Sciences, Inc. (SGHT) Q1 2025 Earnings Call Transcript Sight Sciences, Inc. (NASDAQ:SGHT ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Hannah Jefferies - Investor Relations Paul Badawi - Co-Founder & CEO Ali Bauerlein - CFO Matt Link - Chief Commercial Officer Conference Call Participants Tom Stephan - Stifel Danielle Antalffy - UBS Joanne Welsh - Citi Frank Takkinen - Lake Street Capital Markets Macauley Kilbane - William Blair David Saxon - Needham & Company Operator Good day, and thank you for standing by. Welcome to the Sight Sciences First Quarter 2025 Earnings Results Conference Call. seekingalpha.com - 1 month ago
Sight Sciences (SGHT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates While the top- and bottom-line numbers for Sight Sciences (SGHT) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com - 1 month ago
Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Tops Revenue Estimates Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.33 per share a year ago. zacks.com - 1 month ago
Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the first quarter ended March 31, 2025, reaffirms revenue guidance for full year 2025, and announces improved adjusted operating expenses guidance for full year 2025. globenewswire.com - 1 month ago
Sight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025 MENLO PARK, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the first quarter ended March 31, 2025, after the market close on Thursday, May 8, 2025. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. globenewswire.com - 1 month ago
Sight Sciences Announces the Release of its Sustainability Report MENLO PARK, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that it has published its annual Sustainability Report, highlighting the Company's sustainability activities, performance and results from the last three years. globenewswire.com - 1 month ago
Sight Sciences Appoints Gary Burbach to its Board of Directors MENLO PARK, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that Gerhard (Gary) F. Burbach was appointed to the Company's Board of Directors on April 21, 2025. Mr. Burbach will serve as a Class II director with a term expiring at the 2026 Annual Meeting of Stockholders. globenewswire.com - 1 month ago
Sight Sciences to Debut OMNI® Edge Surgical System at the 2025 ASCRS Annual Meeting, Expanding the OMNI Product Portfolio New system features higher viscoelastic capacity and TruSync™ technology, engineered to safely synchronize surgical control and precision in implant-free, comprehensive MIGS New system features higher viscoelastic capacity and TruSync™ technology, engineered to safely synchronize surgical control and precision in implant-free, comprehensive MIGS globenewswire.com - 1 month ago
Sight Sciences to Present at the 24th Annual Needham Healthcare Conference on April 8th MENLO PARK, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced plans to present at the 24th Annual Needham Healthcare Conference being held virtually. globenewswire.com - 2 months ago
Sight Sciences, Inc. (SGHT) Q4 2024 Earnings Conference Call Transcript Sight Sciences, Inc. (NASDAQ:SGHT ) Q4 2024 Earnings Conference Call March 5, 2025 4:30 PM ET Company Participants Philip Trip Taylor - IR Paul Badawi - Co-Founder & CEO Alison Bauerlein - CFO Matt Link - Chief Commercial Officer Conference Call Participants Danielle Antalffy - UBS Tom Stephan - Stifel Frank Takkinen - Lake Street Capital Markets David Saxon - Needham & Company Phil Dantoin - Piper Sandler Macauley Kilbane - William Blair Operator Hello, and welcome to the Sight Sciences Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com - 3 months ago
Compared to Estimates, Sight Sciences (SGHT) Q4 Earnings: A Look at Key Metrics While the top- and bottom-line numbers for Sight Sciences (SGHT) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com - 3 months ago
8. Profile Summary

Sight Sciences, Inc. SGHT

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 217 M
Dividend Yield 0.00%
Description Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Contact 4040 Campbell Avenue, Menlo Park, CA, 94025 https://www.sightsciences.com
IPO Date July 15, 2021
Employees 216
Officers Mr. Steve R. Tamayo Jr. Vice President and Chief Ethics & Compliance Officer Mr. Brenton Taylor Executive Vice President of Operations Dr. David Badawi M.D. Co-Founder, Chief Technology Officer & Director Dr. Reay H. Brown M.D. Chief Medical Officer Dr. Manohar K. Raheja Ph.D. Executive Vice President of Research & Development Mr. Paul Badawi Co-Founder, President, Chief Executive Officer & Director Ms. Alison Perry Bauerlein Chief Financial Officer, Principal Financial & Accounting Officer and Treasurer Mr. Jeremy B. Hayden J.D. Chief Legal Officer & Corporate Secretary Mr. Matthew W. Link Chief Commercial Officer Mr. Jim Rodberg Vice President of Finance & Corporate Controller